June 25, 2017 | Press Release

Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 And HAVEN 2) in Hemophilia A With Inhibitors

June 22, 2017 | Press Release

FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers

June 22, 2017 | News Feature

FDA Approves New Time-Saving Treatment Option for People with Certain Blood Cancers

On June 22, 2017, the FDA approved a Genentech medicine for subcutaneous (under the skin) injection for the treatment of certain blood cancers.

View information and materials

June 22, 2017 | Press Release

New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

June 5, 2017 | Press Release

APHINITY Study Shows Genentech’s Perjeta-Based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Herceptin and Chemotherapy in HER2-Positive Early Breast Cancer

June 5, 2017 | Press Release

Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type of Lung Cancer

May 22, 2017 | Press Release

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis

May 10, 2017 | Press Release

Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2017 | Press Release

Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Bladder Cancer

April 25, 2017 | Press Release

New Data at AAN Reinforce Clinical Benefit of Genentech’s Ocrevus (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis

April 18, 2017 | Press Release

Genentech to Present New Data at AAN Reinforcing Efficacy And Safety of Newly FDA Approved Ocrevus (Ocrelizumab) in Two Types of Multiple Sclerosis

April 17, 2017 | Press Release

FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States

April 17, 2017 | News Feature

FDA Approves New Option for Certain People with Advanced Bladder Cancer

On April 17, 2017, the FDA granted accelerated approval to a Genentech cancer immunotherapy medicine as an initial treatment for certain people with advanced bladder cancer.

View information and materials

April 17, 2017 | News Feature

FDA Approves New Treatment Option for People with Diabetic Retinopathy

On April 17, 2017, the FDA granted approval to a Genentech medicine for the monthly treatment of all forms of diabetic retinopathy, a potentially blinding eye disease.

View information and materials

April 17, 2017 | Press Release

FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer

April 16, 2017 | Press Release

Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A

April 9, 2017 | Press Release

Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

March 29, 2017 | Press Release

FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

March 28, 2017 | News Feature

FDA Approves New Medicine for Relapsing and Primary Progressive Forms of Multiple Sclerosis

On March 28, the FDA approved the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.

View information and materials

March 28, 2017 | Press Release

FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis

March 23, 2017 | Press Release

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

March 1, 2017 | Press Release

Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy

February 17, 2017 | Press Release

Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People with Locally Advanced or Metastatic Renal Cell Carcinoma

January 23, 2017 | Press Release

FDA Grants Priority Review For Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis

January 8, 2017 | Press Release

FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer

January 5, 2017 | Press Release

FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization

December 21, 2016 | Press Release

Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study

December 21, 2016 | Press Release

Positive Phase III Results of Genentech’s Investigational Medicine Ocrevus™ (Ocrelizumab) Published in New England Journal of Medicine

December 20, 2016 | Press Release

FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)

December 6, 2016 | News Feature

FDA Approves Medicine for Women with Platinum-Sensitive Recurrent Ovarian Cancer

On December 6, 2016 the FDA approved a medicine for women with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

View information and materials

October 18, 2016 | News Feature

FDA Approves New Immunotherapy Medicine for a Type of Metastatic Lung Cancer

On October 18, 2016, the FDA granted approval to a new cancer immunotherapy medicine for the treatment of a type of metastatic lung cancer.

View information and materials

September 16, 2016 | News Feature

Flu Season Resources

On average, 5-20% of the US population gets the flu each year, and more than 200,000 are hospitalized from seasonal flu related complications. To recognize flu symptoms, remember Flu F.A.C.T.S. (Fever, Aches, Chills, (extreme) Tiredness, and Sudden Onset).

View information and materials

May 18, 2016 | News Feature

FDA Approves New Immunotherapy Medicine for Specific Type of Advanced Bladder Cancer

On May 18, 2016, the FDA granted accelerated approval to a new cancer immunotherapy medicine for the treatment of a specific type of advanced bladder cancer.

View information and materials

April 11, 2016 | News Feature

FDA Approves New Treatment Option for Hard-To-Treat Type of Chronic Lymphocytic Leukemia

On April 11, 2016, the FDA granted accelerated approval to a new medicine for the treatment of a hard-to-treat type of chronic lymphocytic leukemia.

View information and materials

February 26, 2016 | News Feature

FDA Approves New Option For Certain People With Previously Treated Follicular Lymphoma

On February 26, 2016, the FDA approved a Genentech medicine for people with follicular lymphoma whose disease did not respond to or returned after treatment with another medicine.

View information and materials

December 11, 2015 | News Feature

FDA Approves New Treatment Option for Specific Type of Lung Cancer

On December 11, 2015, the FDA granted accelerated approval to a new medicine for the treatment of a specific type of lung cancer.

View information and materials

November 10, 2015 | News Feature

FDA Approves New Treatment Option for Advanced Melanoma

On November 10, 2015, the FDA approved a new medicine for the treatment of advanced melanoma.

View information and materials

February 6, 2015 | News Feature

FDA Approves Genentech Medicine for Diabetic Retinopathy in People with Diabetic Macular Edema

On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).

View information and materials

November 14, 2014 | News Feature

FDA Approves Genentech Medicine for Women with Platinum-Resistant Recurrent Ovarian Cancer

On November 14, 2014, a Genentech medicine received FDA approval for the treatment of women with platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received no more than two prior chemotherapy regimens.

View information and materials

October 15, 2014 | News Feature

FDA Approves Medicine for Idiopathic Pulmonary Fibrosis

On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).

View information and materials

August 14, 2014 | News Feature

FDA Approves Genentech Medicine for Women with Advanced Cervical Cancer

On August 14, 2014, a Genentech medicine received FDA approval for use in persistent, recurrent or metastatic cervical cancer. It is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.

View information and materials

July 1, 2014 | News Feature

Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals

On July 1, 2014, Genentech entered into an agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California.

View information and materials

March 21, 2014 | News Feature

FDA Approves Xolair® (omalizumab) for Subcutaneous Use for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives

On March 21, 2014, the FDA approved a Genentech medicine for people 12 years of age and older for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives.

View information and materials

December 5, 2013 | News Feature

ASH 2013: Press Releases, Fact Sheets & More

We're presenting important new findings on unapproved and investigational medicines at ASH 2013. Read press releases and learn about our presence at ASH this year.

View information and materials

November 1, 2013 | News Feature

FDA Approves New Genentech Medicine for Chronic Lymphocytic Leukemia (CLL)

On November 1, 2013, the FDA approved a new Genentech medicine for people with previously untreated CLL. It was the first medicine approved with the FDA’s Breakthrough Therapy Designation.

View information and materials

May 15, 2013 | News Feature

2013 ASCO Annual Meeting

Genentech to report new advances at the American Society of Clinical Oncology Annual MeetingGenentech will present important new data from studies of several cancer medicines at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013, in Chicago.This page is intended to be a media resource for Genentech developments at ASCO. It will be updated frequently throughout the meeting.

View information and materials

May 14, 2013 | News Feature

FDA Approves First Personalized Medicine for EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer in the United States

On May 14, 2013, the FDA approved a personalized medicine for people newly diagnosed with a genetically distinct type of metastatic NSCLC.

View information and materials

May 10, 2013 | News Feature

Celebrating the 60th Anniversary of Watson & Crick’s Discovery

Genentech built an iPad app that turns a primary genetic concept into a maddeningly addictive mobile game.

View information and materials

January 23, 2013 | News Feature

FDA Approves New Use of Avastin Plus Fluoropyrimidine-Based Chemotherapy in Metastatic Colorectal Cancer

On January 23, 2013, a Genentech medicine received FDA approval for a new use in metastatic colorectal cancer.

View information and materials

October 12, 2012 | News Feature

FDA Approves Expanded Indication for Actemra in RA

On October 12, 2012, a Genentech medicine received approval from the FDA to expand its indication for Rheumatoid Arthritis.

View information and materials

August 25, 2012 | News Feature

Genentech's gRide Program Achieves Landmark Milestone

gRide, Genentech's employee commuting program, has saved 100 million miles of driving since the program's inception began in late 2006. The program began as a way to reduce the number of vehicles that travel to and park on the South San Francisco campus.

View information and materials

August 10, 2012 | News Feature

Lucentis Approved for Treatment of Diabetic Macular Edema (DME)

On August 10, 2012, a Genentech medicine was approved by the FDA for diabetic macular edema (DME).

View information and materials

June 11, 2012 | News Feature

Genentech Gives Back Week 2012

Genentech Gives Back Week (June 11 - 16, 2012) is a unique opportunity for Genentech employees to support the communities where we live and work.

View information and materials

June 8, 2012 | News Feature

Perjeta Approved For HER2-Positive Metastatic Breast Cancer

On June 8, 2012, a Genentech medicine was approved by the FDA for previously untreated HER2-positive metastatic breast cancer.

View information and materials

May 30, 2012 | News Feature

Genentech at ASCO 2012

Genentech will present important new data on several cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).

View information and materials

May 17, 2012 | News Feature

Landmark Alzheimer's Prevention Trial

Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.

View information and materials

January 30, 2012 | News Feature

Erivedge Approved For Advanced Basal Cell Carcinoma

On January 30, 2012, a Genentech medicine was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

View information and materials

August 17, 2011 | News Feature

Genentech Medicine Approved For Certain Type Of Melanoma

On August 17, 2011, a Genentech medicine was approved by the FDA for a type of inoperable or metastatic melanoma.

View information and materials

October 20, 2010 | News Feature

Genentech Medicine Approved in Stomach Cancer

On October 20, 2010, a Genentech medicine was approved by the U.S. Food and Drug Administration (FDA) for stomach cancer.

View information and materials

October 18, 2010 | News Feature

25th Anniversary of First Product Approval

October 18, 2010 is the 25th anniversary of Genentech's first product approval and the first recombinant biotech drug to be manufactured and marketed by a biotechnology company.

View information and materials

September 21, 2010 | News Feature

Napoleone Ferrara Named 2010 Lasker Award Winner

Genentech Fellow Napoleone Ferrara is the winner of the 2010 Lasker Award for clinical research, presented annually to an investigator "whose contributions have improved the clinical treatment of patients."

View information and materials

September 13, 2010 | News Feature

Genentech Goes to Town 2010

Genentech Goes to Town takes place September 13 to September 24 in South San Francisco, Vacaville, Oceanside and Hillsboro. The Genentech Goes to Town program supports our communities by providing employees with special "GenenMoney" to spend at local businesses.

View information and materials

June 14, 2010 | News Feature

Genentech Gives Back Week 2010

Genentech Gives Back Week voluntary activities each day that help Genentech employees collectively make a difference in our communities. All employees are invited to participate in Genentech Gives Back as their time and interest allows.

View information and materials